Another Bite Out Of Apple, Eli Lilly’s Direct Approach 1/4/23
Another day, another downgrade for Apple’s stock – the second this week. The shares are down more than 5% to start the year, as concerns over iPhone demand grow. We’ll speak to the analyst behind the latest call. Plus, Eli Lilly is taking weight-loss drugs directly to the consumer, setting up a new service to help patients get telehealth prescriptions. We’ll ask a medical doctor about the potential implications.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Another day, another downgrade for Apple’s stock – the second this week. The shares are down more than 5% to start the year, as concerns over iPhone demand grow. We’ll speak to the analyst behind the latest call. Plus, Eli Lilly is taking weight-loss drugs directly to the consumer, setting up a new service to help patients get telehealth prescriptions. We’ll ask a medical doctor about the potential implications.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.